BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 2167452)

  • 1. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation.
    Sullivan KM; Kopecky KJ; Jocom J; Fisher L; Buckner CD; Meyers JD; Counts GW; Bowden RA; Peterson FB; Witherspoon RP
    N Engl J Med; 1990 Sep; 323(11):705-12. PubMed ID: 2167452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
    Winston DJ; Ho WG; Bartoni K; Champlin RE
    Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease.
    Sullivan KM
    Clin Exp Immunol; 1996 May; 104 Suppl 1():43-8. PubMed ID: 8625543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group.
    Schmidt GM; Horak DA; Niland JC; Duncan SR; Forman SJ; Zaia JA
    N Engl J Med; 1991 Apr; 324(15):1005-11. PubMed ID: 1848679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts.
    Feinstein LC; Seidel K; Jocum J; Bowden RA; Anasetti C; Deeg HJ; Flowers ME; Kansu E; Martin PJ; Nash RA; Storek J; Etzioni R; Applebaum FR; Hansen JA; Storb R; Sullivan KM
    Biol Blood Marrow Transplant; 1999; 5(6):369-78. PubMed ID: 10595814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of immunoglobulin in bone marrow transplantation.
    Saral R
    Transplant Proc; 1991 Aug; 23(4):2128-32. PubMed ID: 1871829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels.
    Cottler-Fox M; Lynch M; Pickle LW; Cahill R; Spitzer TR; Deeg HJ
    Bone Marrow Transplant; 1991 Jul; 8(1):27-33. PubMed ID: 1655138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin in bone marrow transplantation.
    Gale RP; Winston D
    Cancer; 1991 Sep; 68(6 Suppl):1451-3. PubMed ID: 1652350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation.
    Winston DJ; Ho WG; Lin CH; Bartoni K; Budinger MD; Gale RP; Champlin RE
    Ann Intern Med; 1987 Jan; 106(1):12-8. PubMed ID: 3024542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin therapy in bone marrow transplantation.
    Sullivan KM
    Am J Med; 1987 Oct; 83(4A):34-45. PubMed ID: 2823602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery.
    Sullivan KM; Storek J; Kopecky KJ; Jocom J; Longton G; Flowers M; Siadak M; Nims J; Witherspoon RP; Anasetti C; Appelbaum FR; Bowden RA; Buckner CD; Crawford SW; Deeg HJ; Hansen JA; McDonald GB; Sanders JE; Storb R
    Biol Blood Marrow Transplant; 1996 Feb; 2(1):44-53. PubMed ID: 9078354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cytomegalovirus hyperimmune globulin prophylaxis in bone marrow transplants in children with various diseases].
    Ebell W; Blütters-Sawatzki R; Friedrich W; Hampl W; Kleihauer E
    Immun Infekt; 1985 Nov; 13(6):307-12. PubMed ID: 3000925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?
    Klaesson S; Ringdén O; Ljungman P; Aschan J; Hägglund H; Winiarski J
    Transplantation; 1995 Dec; 60(11):1225-30. PubMed ID: 8525515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation.
    Meyers JD; Reed EC; Shepp DH; Thornquist M; Dandliker PS; Vicary CA; Flournoy N; Kirk LE; Kersey JH; Thomas ED
    N Engl J Med; 1988 Jan; 318(2):70-5. PubMed ID: 2827025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful strategy for prevention of cytomegalovirus interstitial pneumonia after human leukocyte antigen-identical bone marrow transplantation.
    Elfenbein GJ; Siddiqui T; Rand KH; Graham-Pole J; Marcus RB; Mendenhall NP; Goedert TM; Wikle-Fisher T; Gross SA; Weiner RS
    Rev Infect Dis; 1990; 12 Suppl 7():S805-10. PubMed ID: 2173109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources.
    Rocha V; Wagner JE; Sobocinski KA; Klein JP; Zhang MJ; Horowitz MM; Gluckman E
    N Engl J Med; 2000 Jun; 342(25):1846-54. PubMed ID: 10861319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation.
    Siadak MF; Kopecky K; Sullivan KM
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):53-7. PubMed ID: 8033436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
    Atkinson K; Arthur C; Bradstock K; Dale B; Downs K; Gibson J; Golenia M; Ho J; Joshua D; Juttner C
    Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.